Prelude Therapeutics Files 8-K Report

Ticker: PRLD · Form: 8-K · Filed: Apr 25, 2025 · CIK: 1678660

Sentiment: neutral

Topics: 8-K, regulatory-filing, pharmaceutical

TL;DR

Prelude Therapeutics filed an 8-K on 4/25/25 covering other events and financials.

AI Summary

On April 25, 2025, Prelude Therapeutics Incorporated filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporated in Delaware with its principal executive offices located at 175 Innovation Boulevard, Wilmington, DE 19805. The report covers 'Other Events' and 'Financial Statements and Exhibits'.

Why It Matters

This 8-K filing serves as a public record of significant events or financial updates for Prelude Therapeutics, providing transparency to investors and the market.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not contain information that inherently suggests a high-risk event.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is a current report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, covering 'Other Events' and 'Financial Statements and Exhibits'.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on April 25, 2025.

What is Prelude Therapeutics Incorporated's principal executive office address?

The principal executive offices are located at 175 Innovation Boulevard, Wilmington, Delaware 19805.

What is Prelude Therapeutics Incorporated's Standard Industrial Classification code?

The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

What is the SEC file number for Prelude Therapeutics Incorporated?

The SEC file number for Prelude Therapeutics Incorporated is 001-39527.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 25, 2025 regarding Prelude Therapeutics Inc (PRLD).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing